Metastatic breast cancer case studies
After refusing to receive any treatment for the tumor for 3 years, she was eventually hospitalized at a university hospital located in Seoul due to severe back pain, jaundice, and ascites.
Breast cancer case write up
Bone metastasis was still present. Liver function tests transaminases, bilirubin, and alkaline phosphatase should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. This case report highlights the importance of a high index of clinical suspicion for metastatic disease in a patient with a previous history of breast malignancy, ILC in particular, presenting with new GI symptoms. At the initial presentation in May , complete blood count, renal and liver function tests were normal, C-reactive protein was not elevated. Gastroduodenoscopy confirmed an infiltrated stomach wall at the greater curvature, but biopsies could not confirm malignancy. After chemo-port insertion, on October 28, , first-line trastuzumab and paclitaxel treatment was performed by using palliative chemotherapy, followed by ascites and pleural effusion puncture. Medical imaging showed mesenterial metastases and CA Early recognition and correct diagnosis is important for an adequate therapeutic strategy [ 9 , 14 ]. After having received chemotherapy with paclitaxel and trastuzumab, the patient decided to suspend chemotherapy due to vancomycin-resistant enterococci VRE and general weakness. There was no history of rectal bleeding. Causality of the deaths is uncertain. With an ageing population and an increasing number of cancer survivors we might expect to encounter more unusual presentations with distant metastasis in the near future [ 9 , 10 , 12 ]. She was treated with denosumab and hormonal therapy: first with tamoxifen, which was later on replaced by letrozole and eventually by exemestane due to progressive bone metastases. Immunohistochemical staining was positive for estrogen receptor ER and progesterone receptor PR and negative for human epidermal growth factor receptor 2 HER2-neu. Case 1 A woman in her 60s was diagnosed with node-positive invasive ductal breast cancer in October
As GI tract involvement is mostly seen with extensive metastatic disease, prognosis is still poor. ILC has a metastatic rate of 4.
Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TYKERB and for 1 week after the last dose. Treatment guidelines recommend endocrine therapy in this setting when possible, due to its lower toxicity profile compared with that for chemotherapy.
When compared to the test carried out on October 19,the PET-CT result on August 8,showed a significant reduction of the tumor size in the right breast, the primary site of the tumor, as well as of the right axillary lymph node, liver, and bone metastases.
Breast cancer report case study
Although endoscopy with biopsy remains the best diagnostic method, it can give false negative results, for example when the tumor is submucosal. Described herein are cases of two women who developed MBC following adjuvant chemotherapy and endocrine therapy for human epidermal growth factor receptor 2 HER2 -negative ductal carcinoma. Both underwent treatment with fulvestrant, followed by paclitaxel and letrozole or nab-paclitaxel. Invasive lobular carcinoma ILC is the second most common type of invasive breast cancer, following ductal adenocarcinoma. After chemo-port insertion, on October 28, , first-line trastuzumab and paclitaxel treatment was performed by using palliative chemotherapy, followed by ascites and pleural effusion puncture. Contraindication: TYKERB is contraindicated in patients with known severe hypersensitivity eg, anaphylaxis to this product or any of its components. Keywords: Korean medicine therapy, Breast cancer, Wild ginseng pharmacopuncture, Soramdan S, Hae, Jeobgoldan Introduction Breast cancer is the second most prevalent cancer among women following thyroid cancer. They can also mimic a primary cancer of the GI tract, which is more common than isolated GI metastasis of primary BC [ 2 , 5 ]. Many patients are treated with chemotherapy, hormonal therapy or a combination of both. Bone metastasis was still present.
Anorectal involvement is very rare [ 1314 ]. However, the chemo-port was removed due to port infection. GI metastasis is usually associated with extensive systemic spread [ 8 ].
based on 23 review